August 14, 2019 QUARTERLY REPORT – 2019 Q2
Posted at 09:01h
in Uncategorized
Vaccibody - Quarterly report 2019 Q2...
June 26, 2019 VACCIBODY ANNOUNCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES INDUCED IN CANCER PATIENTS WITH LOW MUTATIONAL BURDEN AFTER VB10.NEO VACCINATION
Posted at 17:00h
in Uncategorized
VACCIBODY ANNOUNCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES INDUCED IN CANCER PATIENTS WITH LOW MUTATIONAL BURDEN AFTER VB10.NEO VACCINATION ...
June 26, 2019 VACCIBODY ANNOUNCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES INDUCED IN CANCER PATIENTS WITH LOW MUTATIONAL BURDEN AFTER VB10.NEO VACCINATION
Posted at 16:02h
in Uncategorized
VACCIBODY ANNOUNCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES INDUCED IN CANCER PATIENTS WITH LOW MUTATIONAL BURDEN AFTER VB10.NEO VACCINATION ...
May 24, 2019 QUARTERLY REPORT – 2019 Q1
Posted at 21:30h
in Uncategorized
Vaccibody - Quarterly report 2019 Q1...
May 7, 2019 VACCIBODY CALLS FOR ANNUAL GENERAL MEETING.
Posted at 10:57h
in Uncategorized
Vaccibody calls for Annual General Meeting to be held on May 13, 2019 at 10.00 AM in Forskningsparken, Oslo. Shareholders will receive the call documents electronically or by post. The call documents can also be downloaded here. ...
April 1, 2019 VACCIBODY AS AND NEKTAR THERAPEUTICS PRESENT NEW PRECLINICAL DATA FROM THEIR IMMUNO-ONCOLOGY COLLABORATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2019
Posted at 23:00h
in Uncategorized
Oslo/San Francisco, April 1, 2019 – Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist. These data were presented today in a...
March 25, 2019 POSITIVE 12-MONTH RESULTS FROM PHASE IIa CLINICAL STUDY IN HIGH GRADE CERVICAL DYSPLASIA PROVIDES PROOF-OF-CONCEPT FOR VACCIBODY’S IMMUNOTHERAPY PLATFORM AND LEAD CANDIDATE VB1O.16
Posted at 10:00h
in Uncategorized
Oslo, March 25, 2019 Vaccibody AS today announced positive 12-month results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial...
February 27, 2019 VACCIBODY AS TO PRESENT DATA ON VB10.NEO AND VB10.16 AT UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
Posted at 22:30h
in Uncategorized
Poster presentations of Vaccibody’s two lead candidates: 6M interim clinical data on VB10.16, and preclinical data on VB10.NEO alone and in combination with bempegaldesleukin (NKTR-214) Oslo, Norway, February 27th, 2019 – Vaccibody AS today announced that clinical and preclinical data will be presented at the upcoming 2019...
February 14, 2019 VACCIBODY AS – NOK 230 MILLION (EUR 23.6 MILLION) PRIVATE PLACEMENT SUCCESSFULLY PLACED
Posted at 13:21h
in Uncategorized
Reference is made to the press release by Vaccibody AS ("Vaccibody" or the "Company") on 13 February 2019 regarding a contemplated offer of new shares (the "Offer Shares") in a private placement to raise gross proceeds of approximately NOK 230 million (the "Private Placement"). The...
February 13, 2019 COMPANY PRESENTATION – February 2019
Posted at 08:15h
in Uncategorized
Download presentation...